{"input_url":"https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html","gnews_decode":"https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html","http_status":200,"final_url":"https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html","html_length":75300,"trafilatura_result":"ok","text_length":4554,"text_preview":"An advisory committee to the US Food and Drug Administration (FDA) voted 8-6 with one abstention on Thursday to recommend that two peptides – BPC-157 to treat ulcerative colitis and KPV for wound treatment and inflammatory conditions – be added to the list of drugs eligible for bulk compounding, kno","verdict":"OK"}